Нефрология / 01. ХГН и ХБП / Клинические практические рекомендации KDIGO

ЛИТЕРАТУРА

672.Spetie D.N., Tang Y., Rovin B.H. et al. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int. 2004; 66: 2411–2415.

673.Szeto C.C., Kwan В.С., Lai F.M. et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford). 2008; 47: 1678–1681.

674.Ruiz-lrastorza G., Ramos-Casals M., Brito-Zeron P. et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann. Rheum. Dis. 2010; 69: 20–28.

675.Tsakonas E., Joseph L., Esdaile J.M. et al. A longterm study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus. 1998; 7: 80–85.

676.Siso A., Ramos-Casals M., Bove A. et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus. 2008;

17:281–288.

677.Kaiser R., Cleveland C.M., Criswell L.A. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi ethnic cohort. Ann. Rheum. Dis. 2009; 68: 238–241.

678.Pons-Estel G.J., Alarcon G.S., McGwin Jr G. et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis. Rheum. 2009; 61: 830–839.

679.Illei G.G., Takada K., Parkin D. et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized­ controlled studies. Arthritis. Rheum. 2002; 46: 995–1002.

680.Esdaile J.M., Joseph L., MacKenzie T. et al. The pathogenesis and prognosis of lupus nephritis: information from repeat renal biopsy. Semin Arthritis. Rheum. 1993; 23: 135–148.

681.Daleboudt G.M.N., Bajema I.M., Goemaere N.N.T. et al. The clinical relevance of a repeat biopsy in lupus nephritis flares. Nephrol. Dial. Transplant. 2009; 24: 3712–3717.

682.Birmingham D.J., Nagaraja H.N., Rovin B.H. et al. Fluctuation in self-perceived stress and increased risk of flare in patients with lupus nephritis carrying the serotonin receptor 1A-1019 G allele. Arthritis. Rheum. 2006; 54: 3291–3299.

683.Clough J.D., Lewis E.J., Lachin J.M. Treatment protocols of the lupus nephritis collaborative study of plasmapheresis in severe lupus nephritis. The Lupus Nephritis Collaborative­ Study Group. Prog. Clin. Biol. Res. 1990; 337: 301–307.

684.Linnik M.D., Hu J.Z., Heilbrunn K.R. et al. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis. Rheum. 2005; 52: 1129–1137.

685.Rovin B.H., Song H., Birmingham D.J. et al. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J. Am. Soc. Nephrol. 2005; 16: 467–473.

686.Rovin B.H., Nadasdy G., Nuovo G.J. et al. Expression of adiponectin and its receptors in the kidney during SLE nephritis (abstract). J. Am. Soc. Nephrol. 2006; 17: 256A.

687.Rovin B.H., Stillman I.E. Kidney. In: Lahita R.G., Tsokos G.T., Buyon J.P., Koike T. (eds). Systemic Lupus Erythematosus, 5th edn. Elsevier: Waltham, MA, 2011; 769–814.

161

688.Garcia-Carrasco M., Mendoza-Pinto C., SandovalCruz M. et al. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients. Lupus. 2010; 19: 213–219.

689.Rauova L., Lukac J., Levy Y. et al. High-dose intravenous immunoglobulins for lupus nephritis – a salvage immunomodulation. Lupus. 2001; 10: 209–213.

690.Ogawa H., Kameda H., Amano К. et al. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus. 2010;

19:162–169.

691.Ogawa H., Kameda H., Nagasawa H. et al. Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. Mod. Rheumatol. 2007; 17: 92–97.

692.Miyasaka N., Kawai S., Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod. Rheumatol. 2009; 19: 606–615.

693.Daugas E., Nochy D., Huong D.L. et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J. Am. Soc. Nephrol. 2002; 13: 42–52.

694.Tektonidou M.G. Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy. Clin. Rev. Allergy. Immunol. 2009; 36: 131–140.

695.Tektonidou M.G., Sotsiou F., Moutsopoulos H.M. Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS. J. Rheumatol. 2008; 35: 1983–1988.

696.Crowther M.A., Ginsberg J.S., Julian J. et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N. Engl. J. Med. 2003; 349: 1133–1138.

697.Finazzi G., Marchioli R., Brancaccio V. et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J. Thromb. Haemost. 2005; 3: 848–853.

698.Kwok S.K., Ju J.H., Cho C.S. et al. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: a single centre study. Lupus. 2009; 18: 16–21.

699.Tandon A., Ibanez D., Gladman D.D. et al. The effect of pregnancy on lupus nephritis. Arthritis. Rheum. 2004;

50:3941–3946.

700.Carvalheiras G., Vita P., Marta S. et al. Pregnancy and systemic lupus erythematosus: review of clinical features and outcome of 51 pregnancies at a single institution. Clin. Rev. Allergy. Immunol. 2010; 38: 302–306.

701.Imbasciati E., Tincani A., Gregorini G. et al. Pregnancy in women with pre­existing lupus nephritis: predictors of fetal and maternal outcome. Nephrol. Dial. Transplant. 2009; 24: 519–525.

702.Wagner S.J., Craici I., Reed D. et al. Maternal and foetal outcomes in pregnant patients with active lupus nephritis. Lupus. 2009; 18: 342–347.

703.Levy R.A., Vilela V.S., Cataldo M.J. et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus. 2001; 10: 401–404.

704.Hogan S.L., Nachman P.H., Wilkman A.S. et al. Prognostic markers in patients with antineutrophil cyto-

162

plasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J. Am. Soc. Nephrol. 1996; 7: 23–32.

705.de Groot K., Harper L., Jayne D.R. et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann. Intern. Med. 2009; 150: 670–680.

706.Hogan S.L., Falk R.J., Chin H. et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann. Intern. Med. 2005; 143: 621–631.

707.Jayne D.R., Gaskin G., Rasmussen N. et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J. Am. Soc. Nephrol. 2007; 18: 2180–2188.

708.de Lind van Wijngaarden R.A., Hauer H.A., Wolterbeek R. et al. Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis. J. Am. Soc. Nephrol. 2007; 18: 2189–2197.

709.Nachman P.H., Hogan S.L., Jennette J.C. et al. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J. Am. Soc. Nephrol. 1996; 7: 33–39.

710.Walters G.D., Willis N.S., Craig J.C. Interventions for renal vasculitis in adults. A systematic review. ВМС Nephrol. 2010; 11: 12.

711.Jayne D., Rasmussen N., Andrassy К. et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 2003; 349: 36–44.

712.Guillevin L., Cohen P., Mahr A. et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis. Rheum. 2003; 49: 93–100.

713.Jones R.B., Tervaert J.W., Hauser T. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N .Engl. J. Med. 2010; 363: 211–220.

714.Stone J.H., Merkel P.A., Spiera R. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 2010; 363: 221–232.

715.Cole E., Cattran D., Magil A. et al. A prospective randomized trial of plasma exchange as additive therapy in idio­ pathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am. J. Kidney. Dis. 1992; 20: 261–269.

716.Lauque D., Cadranel J., Lazor R. et al. Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Groupe d’Etudes et de Recherche sur les Maladies «Orphelines» Pulmonaires (GERM«O»P).

Medicine (Baltimore). 2000; 79: 222–233.

717.Klemmer P.J., Chalermskulrat W., Reif M.S. et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am. J. Kidney. Dis. 2003; 42: 1149–1153.

718.Holguin F., Ramadan B., Gal A.A. et al. Prognostic factors for hospital mortality and ICU admission in patients with ANCA-related pulmonary vasculitis. Am. J. Med. Sci. 2008; 336: 321–326.

719.Rutgers A., Slot M., van Paassen P. et al. Coexistence of anti-glomerular basement membrane antibodies and

ЛИТЕРАТУРА

myeloperoxidase-ANCAs in crescentic glomerulonephritis.

Am. J. Kidney. Dis. 2005; 46: 253–262.

720.Silva F., Specks U., Kalra S. et al. Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement – a prospective, open-label pilot trial. Clin. J. Am. Soc. Nephrol.2010; 5: 445–453.

721.Stassen P.M., Tervaert J.W., Stegeman C.A. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann. Rheum. Dis. 2007; 66: 798–802.

722.Hu W., Liu C., Xie H. et al. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol. Dial. Transplant. 2008; 23: 1307–1312.

723.Sanders J.S., Huitma M.G., Kallenberg C.G. et al. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumato­ logy (Oxford). 2006; 45: 724–729.

724.Hiemstra T.F., Walsh M., Mahr A. et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010; 304: 2381–2388.

725.Stegeman C.A., Tervaert J.W., de Jong P.E. et al. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N. Engl. J. Med. 1996; 335: 16–20.

726.Pagnoux C., Mahr A., Hamidou M.A. et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N. Engl. J. Med. 2008; 359: 2790–2803.

727.Lionaki S., Hogan S.L., Jennette C.E. et al. The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int. 2009; 76: 644–651.

728.Weidanz F., Day C.J., Hewins P. et al. Recurrences and infections during continuous immunosuppressive therapy after beginning dialysis in ANCA-associated vasculitis. Am. J. Kidney. Dis. 2007; 50: 36–46.

729.Martinez V., Cohen P., Pagnoux С. et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis. Rheum. 2008; 58: 308–317.

730.Dickenmann M., Oettl T., Mihatsch M.J. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes.

Am. J. Kidney. Dis. 2008; 51: 491–503.

731.Jayne D.R., Chapel H., Adu D. et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM. 2000; 93: 433–439.

732.Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J. Intern. Med. 2005; 257: 540–548.

733.Keogh K.A., Wylam M.E., Stone J.H. et al. Induction of remission by В lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis. Rheum. 2005; 52: 262–268.

734.Stasi R., Stipa E., Del Poeta G. et al. Long-term observation of patients with anti-neutrophil cytoplasmic

ЛИТЕРАТУРА

antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford). 2006; 45: 1432–1436.

735.Finkielman J.D., Merkel P.A., Schroeder D. et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann. Intern. Med. 2007; 147: 611–619.

736.Nowack R., Grab I., Flores-Suarez L.F. et al. ANCA titres, even of IgG subclasses, and soluble CD14 fail to predict relapses in patients with ANCA-associated vasculitis.

Nephrol. Dial. Transplant. 2001; 16: 1631–1637.

737.Gera M., Griffin M.D., Specks U. et al. Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression. Kidney Int. 2007; 71: 1296–1301.

738.Nachman P.H., Segelmark M., Westman К. et al. Recurrent ANCA-associated small vessel vasculitis after transplantation: A pooled analysis. Kidney Int. 1999; 56: 1544–1550.

739.Little M.A., Hassan B., Jacques S. et al. Renal transplantation in systemic vasculitis: when is it safe? Nephrol. Dial. Transplant. 2009; 24: 3219–3225.

740.Levy J.B., Turner A.N., Rees A.J. et al. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann. Intern. Med. 2001; 134: 1033–1042.

741.Johnson J.P., Moore Jr J., Austin III H.A. et al. Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore) 1985; 64: 219–227.

742.Jindal K.K. Management of idiopathic crescentic and diffuse proliferative glomerulonephritis: evidence-based recommendations. Kidney Int. Suppl 1999; 70: S33–S40.

743.Cui Z., Zhao M.H., Xin G. et al. Characteristics and prognosis of Chinese patients with anti-glomerular basement membrane disease. Nephron. Clin. Pract. 2005; 99: c49–c55.

744.Levy J.B., Hammad T., Coulthart A. et al. Clinical features and outcome of patients with both ANCA and antiGBM antibodies. Kidney Int. 2004; 66: 1535–1540.

745.Li F.K., Tse К.С., Lam M.F. et al. Incidence and outcome of antiglomerular basement membrane disease in Chinese. Nephrology (Carlton). 2004; 9: 100–104.

746.Lindic J., Vizjak A., Ferluga D. et al. Clinical outcome of patients with coexistent antineutrophil cytoplasmic antibodies and antibodies against glomerular basement membrane. Ther. Apher. Dial. 2009; 13: 278–281.

747.Segelmark M., Hellmark T., Wieslander J. The prognostic significance in Goodpasture’s disease of specificity, titre and affinity of anti-glomerular-basement-membrane antibodies. Nephron. Clin. Pract. 2003; 94: C59–C68.

748.Hirayama K., Yamagata K., Kobayashi M. et al. Antiglomerular basement membrane antibody disease in Japan: part of the nationwide rapidly progressive glomerulonephritis survey in Japan. Clin. Exp. Nephrol. 2008; 12: 339–347.

163

749.Shah M.K., Hugghins S.Y. Characteristics and outcomes of patients with Goodpasture’s syndrome. South Med. J. 2002; 95: 1411–1418.

750.Stegmayr B.G., Almroth G., Berlin G. et al. Plasma exchange or immunoadsorption in patients with rapidly progressive crescentic glomerulonephritis. A Swedish multicenter study. Int. J. Artif. Organs. 1999; 22: 81–87.

751.Proskey A.J., Weatherbee L., Easterling R.E. et al. Goodpasture’s syndrome. A report of five cases and review of the literature. Am. J. Med. 1970; 48: 162–173.

752.Levy J.B., Lachmann R.H., Pusey C.D. Recurrent Goodpasture’s disease. Am. J. Kidney. Dis. 1996; 27: 573–578.

753.Adler S., Bruns F.J., Fraley D.S. et al. Rapid progressive glomerulonephritis: relapse after prolonged remission. Arch. Intern. Med. 1981; 141: 852–854.

754.Hind C.R., Bowman C., Winearls C.G. et al. Recurrence of circulating anti-glomerular basement membrane antibody three years after immunosuppressive treatment and plasma exchange. Clin. Nephrol. 1984; 21: 244–246.

755.Klasa R.J., Abboud R.T., Ballon H.S. et al. Goodpas- ture’ssyndrome:recurrenceafterafive-yearremission.Casere- portandreviewoftheliterature.Am. J. Med. 1988;84:751–755.

756.Choy B.Y., Chan T.M., Lai K.N. Recurrent glomerulonephritis after kidney transplantation. Am. J. Transplant. 2006; 6: 2535–2542.

757.Joshi K., Nada R., Minz M. et al. Recurrent glomerulopathy in the renal allograft. Transplant. Proc. 2007; 39: 734–736.

758.Counsell С. Formulating questions and locating primary studies for inclusion in systematic reviews. Ann. Intern. Med. 1997; 127: 380–387.

759.Atkins D., Best D., Briss P.A. et al. Grading quality of evidence and strength of recommendations. BMJ. 2004; 328: 1490.

760.GuyattG.H.,OxmanA.D.,KunzR.etal.Goingfrom evidence to recommendations. BMJ. 2008; 336: 1049–1051.

761.Uhlig K., Macleod A., Craig J. et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 70: 2058–2065.

762.AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project.

Qual Saf Health Care 2003; 12: 18–23.

763.Shiffman R.N., Shekelle P., Overhage J.M. et al. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann. Intern. Med. 2003; 139: 493–498.

764.Finding what Works in Health Care: Standards for Systematic Reviews. IOM (Institute of Medicine): Washington, DC 2011.

765.Clinical Practice Guidelines we can Trust. IOM (Institute of Medicine): Washington, DC 2011.